Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers

Abstract

BackgroundAlthough cholesterol guidelines emphasize cardiovascular disease (CVD) risk to guide primary prevention, predictors of statin use in practice are unknown. We aimed to identify factors associated with a cholesterol treatment discussion and statin prescribing in a high-risk population. MethodsWe used data from a trial conducted among participants in community health centers without CVD or diabetes and a 10-year coronary heart disease (CHD) risk≥10%. Cholesterol treatment discussion was assessed at 6months and statin prescription at 1year. We used logistic regressions to identify factors associated with each outcome. ResultsWe analyzed 646 participants (89% male, mean age 60±9.5years). Cholesterol treatment discussion occurred in 19% and statin prescription in 12% of participants. Ten-year CHD risk was not associated with treatment discussion (OR 1.11 per 1 SD increase, 95% CI 0.91–1.33) but was associated with statin prescription (OR 1.41 per 1 SD increase, 95% CI 1.13–1.75) in unadjusted models. After adjusting for traditional CVD risk factors that contribute to CHD risk, low-density lipoprotein cholesterol (LDL-C) was independently associated with statin prescription (OR 1.82 per 1 SD increase, 95% CI 1.66–1.99). Antihypertensive medication use was independently associated with both cholesterol treatment discussion (OR 3.68, 95% CI 2.35–5.75) and statin prescription (OR 3.98, 95% CI 3.30–4.81). Other drivers of CVD risk (age, smoking, and systolic blood pressure) were not associated with statin use. ConclusionsSingle risk factor management strongly influences cholesterol treatment discussions and statin prescribing patterns. Interventions that promote risk-based statin utilization are needed. Trial registrationClinicaltrials.gov.: NCT01610609